Chris Chandler

Chris Chandler

Auto-generated profile, based on publicly available information

Chris Chandler

School of Psychology, London Metropolitan University, London N7 8DB, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2023 in Psych
Verified
Journal Article
Open access
PDF file
SBSamantha Banbury
Samantha Banbury
CCChris Chandler
Chris Chandler
Joanne LusherJoanne Lusher
Joanne Lusher
Sexual intimacy is a basic human need that is associated with quality of life whereby its absence can significantly impact both interpersonal and personal wellbeing. This systematic review aimed to provide an up-to-date evaluation of the available literature on mindfulness treatments for sexual functioning in women diagnosed with cancer. Electronic searches including PubMed, PsycINFO, Web of Science and registered clinical trials yielded 10 studies that met the inclusion criteria. The results showed that treatment intervention designs varied and included mixed methods, randomised clinical trials, single arm non-randomised trials and those with the absence of any control. Furthermore, both brief and longer-term mindfulness interventions were trialled across different sexual domains. Whilst inconclusive, mindfulness-based interventions appear to support sexual function and quality of life in both early- and post-cancer survivors. However, in some instances, there were outcome inconsistencies in sexual desire, arousal and orgasm. This review has identified a current shortage in research on the effectiveness of mindfulness-based treatments for supporting sexual functioning in women with cancer; and so far, no research has been conducted in palliative care. This unmet need in supporting sexual functioning in women with cancer, including palliative care, carries important implications for both psychosexual and oncological healthcare services as sexual intimacy does not end with cancer diagnosis or prognosis.

15 June 2016 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
PDF file
SCSharon Cox
Sharon Cox
CCChris Chandler
Chris Chandler
ASAndrew Simpson
Andrew Simpson
KRKevin Riggs
Kevin Riggs

7 December 2024 in Medicina
Verified
Journal Article
Open access
PDF file
SBSamantha Banbury
Samantha Banbury
HTHannah Tharmalingam
Hannah Tharmalingam
Joanne LusherJoanne Lusher
Joanne Lusher
SESimon Erridge
Simon Erridge
CCChris Chandler
Chris Chandler
Background and Objectives: The impact of gynaecological cancer and its treatments on sexual intimacy can be profound on female sexuality. However, very few registered clinical trials have addressed sexual intimacy among this cohort. Materials and Methods: This preliminary randomised control trial (RCT) and content analysis assessed the effectiveness of a brief online mindful compassion group intervention adjunct with cannabis suppositories. Eighty-three participants aged between 18 and 50+ years who were at least six months post-cancer treatment were randomly allocated to one of four groups, depending on whether they were already using cannabis suppositories. These included a cannabis-only group (CO), a mindful-compassion group (MC), a combined mindful-compassion and cannabis suppositories group (COCM) and a care-as-usual group (CAU). Measurements of sexual function, sexual self-efficacy, mindful compassion, well-being and quality of life were taken at weeks 0, 4 and 12. Results: Sexual function, including arousal, lubrication and orgasms, improved for both the MC p = 0.002 and COCM p ≤ 0.001 groups; in addition, sexual pain was reduced in the COCM p = 0.008 and CO p ≤ 0.001 groups compared to the CAU and MC groups, where p ≥ 0.05. Feedback suggested that cannabis mediated the effects of mindful compassion and supported well-being, sexual self-efficacy, and quality of life. Participants also voiced a preference for cannabis suppositories when using dilators as part of their treatment and the use of sex toys instead of dilators, suggesting that dilators had negatively impacted their sexuality. Conclusions: These preliminary and exploratory outcomes look promising and provide a foundation for future research to develop varied healthcare options to improve mental health service delivery and quality of life for this cohort.

1 July 2024 in Revista de Psicoterapia
Verified
Journal Article
Open access
PDF file
SBSamantha Banbury
Samantha Banbury
DJDellian Jean-Marie
Dellian Jean-Marie
JLJoanne Lusher
Joanne Lusher
CCChris Chandler
Chris Chandler
JTJohn James Dennis Turner
John James Dennis Turner
Limited clinical trials have evaluated the effectiveness of mindfulness for sexual functioning in men and the existing studies have targeted white male populations. The present study aimed to evaluate the effectiveness of a Mindfulness-Based Cognitive Intervention (MBCI) for erectile dysfunction (ED) in n=68 African Caribbean men aged 31–50 years old A mixed methods approach was adopted to establish the feasibility of a brief online MBCI, using a waitlist-controlled randomised trial with an experimental and delayed group and a content analysis. Participants completed a series of assessments measuring ED, sexual self-efficacy, well-being, and cognitive mindfulness at weeks 0, 4, and 12 (follow-up). They also completed a series of feedback questions on their experiences of the intervention at weeks 0, 4, and 12. Higher levels of erectile functioning, cognitive mindfulness, sexual self-efficacy, and well-being were reported post-intervention and at the 12-week follow-up. A content analysis of participant feedback responses yielded favourable outcomes, with participants suggesting that they continue to engage in cognitive mindfulness exercises to support them in “having better sex”. This research is the first to look at MCBI in African-Caribbean males with ED and demonstrated the effectiveness of this online intervention; however, it warrants replication with a larger group of ethnically and culturally diverse participants with ED.

7 August 2024 in Psychoactives
Verified
Journal Article
Open access
PDF file
SBSamantha Banbury
Samantha Banbury
CCChris Chandler
Chris Chandler
SESimon Erridge
Simon Erridge
FOFrancisco Javier del Río Olvera
Francisco Javier del Río Olvera
JTJohn James Dennis Turner
John James Dennis Turner
Joanne LusherJoanne Lusher
Joanne Lusher
Research on the use of cannabis rectal suppositories for analgesia is limited. Few trials have evaluated the combined use of mindfulness and cannabis suppositories for anodyspareunia in men who have sex with men (MSM). This preliminary study, including a randomised control trial (RCT) and content analysis, assessed the effectiveness of an online mindful-compassion and cannabis suppository intervention among 52 British MSM (aged 18–50) who predominantly identified as bottoms (recipients of anal sex). Participants were randomly allocated to one of four groups based on whether they were using cannabis suppositories: adjunct cannabis suppository and mindful-compassion (CSMF), cannabis suppository only (CS), mindful compassion only (MF) and care as usual/control (CAU). Assessments measuring mindful compassion, sexual functioning, sexual self-efficacy, well-being, and anodyspareunia levels were completed at weeks 0, 4, and 12. Anodyspareunia levels were lower in the CSMF group compared to the other groups (CS/MF/CAU), p = 0.031. Feedback revealed that participants felt mindful compassion potentiated the effects of cannabis suppositories during sexual intimacy, reducing pain and enhancing sexual self-efficacy, sexual functioning, and well-being. This preliminary study warrants larger-scale investigation to establish the role of cannabis suppositories and mindful compassion in reducing anodyspareunia.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
MFMichael B. Foote
Michael B. Foote
HWHenry Walch
Henry Walch
WCWalid Chatila
Walid Chatila
EVEfsevia Vakiani
Efsevia Vakiani
CCChris Chandler
Chris Chandler
ACAndrea Cercek
Andrea Cercek
Appendiceal adenocarcinoma (AC) are rare gastrointestinal tumors that exhibit a heterogeneous spectrum of tumor histology and differentiation patterns. Personalized AC treatments are limited by the lack of robust histopathological or genomic predictors of disease behavior. We utilized the MSK IMPACT sequencing panel to profile genomic signature patterns in somatic mutations, copy number alterations, and germline mutations in a large curated dataset of patients with AC. We evaluated co-occurrence and clonality patterns between frequently altered genes in AC (RAS, GNAS, TP53) to establish five molecular subtypes of mucinous appendiceal adenocarcinoma (MAAP): RAS mutated-only, GNAS mutated, TP53 & KRAS mutated, TP53 mutated-only, and none (all wild-type). In multivariable Cox regression models, patients with RAS mutated-only tumors exhibit a nearly non-lethal disease course compared to other molecular subtypes, including TP53 mutated-only tumors (hazard ratio for death: 75.6, p<0.001). Inclusion of tumor molecular subtype in conventional multivariable models improves model prognostic strength. In addition, MAAP-derived molecular subtypes prognosticate patient survival in a separate cohort of 248 patients with right-sided, mismatch-repair-proficient metastatic colorectal cancer. Molecular characterization of AC also reveals differences in tumor biology and behavior. In addition to an improved prognosis, RAS mutated-only MAAP tumors exhibit significantly lower tumor mutational quantity and aneuploidy compared to other subtypes in multivariable models (p<0.001). Together with clonality patterns, this suggests that RAS mutated-only tumors exhibit a relatively younger molecular age. In a subset of patients with MAAP who underwent cytoreductive surgery, patients with RAS-only tumors demonstrate significantly lower intra-operative assessed peritoneal cancer indices (PCI) compared to patients with other molecular subtypes (p=0.049). Microscopic assessment of surgical samples reveals that RAS mutated-only tumors are significantly less likely (p<0.001) to exhibit destructive metastatic stromal invasion compared to GNAS and TP53 mutated subtypes. Molecular subtype is also a significant independent predictor of both radiographic and biochemical response to first line chemotherapy for patients with AC. Overall, through a comprehensive profiling of the AC mutational landscape we introduce a unique disease entity of RAS-only mutated MAAP that exhibits dramatically low lethality, low peritoneal spread, and decreased tissue invasiveness despite high-risk histological characteristics. The behavior of this clinically-metastatic, but molecularly-young subtype introduces a new characterization of metastatic pathogenesis and risk that may apply to other premalignant and malignant diseases. Citation Format: Michael B. Foote, Henry Walch, Walid Chatila, Efsevia Vakiani, Chris Chandler, Felix Steinrucke, Garrett Nash, Zsofia Stadler, Sebastian Chung, Yelena Kemel, Anna Maio, Margaret Sheehan, Nikolaus Shultz, Luis A. Diaz, Andrea Cercek. Molecular subtypes characterize appendiceal adenocarcinoma genomic evolution and disease behavior [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3474.